It isn’t often that the biotechnology industry gets swamped with plenty of good news, but that’s what has been happening in recent months. Not surprisingly, they have attracted investor interest. A number of new drug approvals, affirmative data, and accelerated sales and earnings growth at the big biotech companies have re-focused attention to the industry. And increased activity in mergers-and-acquisition front has added to the sector’s allure. A robust M&A environment, a key ingredient for a sustainable biotech bull market rally, has helped drive up the price of many biotech stocks.
Hey, check out all the research scientist jobs. Post your resume today!
